Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Equity Bottom-Up

<ul><li>Feature article: Building tomorrow’s AI: How the UK will become the global architect of Trustworthy Intelligence In this month’s feature article, Professor Andy Pardoe, Professor of AI and Chair of the Deep Tech Innovation Centre at the University of Warwick, gives his perspective on the artificial intelligence (AI) industry and how it is advancing at an unprecedented pace, outstripping anything witnessed in previous decades.</li><li>For researchers, industry leaders and investors, understanding the landscape of AI and how it will evolve over the coming years is becoming increasingly important as AI plays a bigger role in every aspect of our professional and personal lives.</li><li> AI is no longer “just another tech wave or bubble.” Unlike previous AI winters, AI technologies are working at scale across many different applications and use-cases, delivering valuable insights and productivity gains.</li></ul>

Feature article: Building tomorrow’s AI: How the UK will become the global architect of Trustworthy Intelligence In this month’s feature article, Professor Andy Pardoe, Professor of AI and Chair of the Deep Tech Innovation Centre at the University of Warwick, gives his perspective on the artificial intelligence (AI) industry and how it is advancing at an unprecedented pace, outstripping anything witnessed in previous decades.For researchers, industry leaders and investors, understanding the landscape of AI and how it will evolve over the coming years is becoming increasingly important as AI plays a bigger role in every aspect of our professional and personal lives. AI is no longer “just another tech wave or bubble.” Unlike previous AI winters, AI technologies are working at scale across many different applications and use-cases, delivering valuable insights and productivity gains.

Chesnara PLC - Hardman & Co Monthly: October 2025

ICG Enterprise Trust plc / Equity Bottom-Up

<ul><li>Feature article: Addressing the “risk off” investment challenge As we approach mid-2025, life remains challenging for many UK companies and their shareholders, and ‒ as a broad generalisation – consensus suggests little will change in the foreseeable future.</li><li> So, are we now facing a real risk of the UK economy stagnating due to lack of funding?</li><li>If that is the case, who is going to take the initiative and avert such a crisis?</li></ul>

Feature article: Addressing the “risk off” investment challenge As we approach mid-2025, life remains challenging for many UK companies and their shareholders, and ‒ as a broad generalisation – consensus suggests little will change in the foreseeable future. So, are we now facing a real risk of the UK economy stagnating due to lack of funding?If that is the case, who is going to take the initiative and avert such a crisis?

ICG Enterprise Trust plc - Hardman & Co Monthly: June 2025

Oxford Nanopore Technologies / Equity Bottom-Up

<ul><li>Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.</li><li>Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.</li><li>Despite this, some companies can still make extremely attractive returns for investors.</li></ul>

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.Despite this, some companies can still make extremely attractive returns for investors.

Arbuthnot Banking Group / Equity Bottom-Up

<ul><li>ABG’s 1H'24 results showed the group’s continued evolution to optimise its franchise value.</li><li>2023 saw the peak benefits from ABG’s relationship deposit franchise in the recent rising rate environment.</li><li>Margins could be widened while still giving customers competitive products.</li></ul>

ABG’s 1H'24 results showed the group’s continued evolution to optimise its franchise value.2023 saw the peak benefits from ABG’s relationship deposit franchise in the recent rising rate environment.Margins could be widened while still giving customers competitive products.

Hardman & Co Arbuthnot Banking Group (ARBB): 1H’24 - optimising the franchise value

<ul><li>The saying goes, the proof of the pudding is in the eating.</li><li>ABG’s 2023 results proved that the strategic positioning of the group, as a relationship bank, has created enormous value.</li><li>Key highlights were i) PBT £47.1m (2022: £20.0m), ii) operating income £178.9m (2022: £137.4m), iii) average net margin 5.7% (2022: 5.1%), iv) EPS +103% to 222.8p, v) total dividend for the year of 46p (2022: 42p), vi) net assets of £252.4m (2022: £212.0m), NAV per share of 1,547p (2022: 1,411p), vii) CET1 ratio of 13.0% (2022: 11.6%), and total capital ratio of 15.2% (2022: 14.0%).</li></ul>

The saying goes, the proof of the pudding is in the eating.ABG’s 2023 results proved that the strategic positioning of the group, as a relationship bank, has created enormous value.Key highlights were i) PBT £47.1m (2022: £20.0m), ii) operating income £178.9m (2022: £137.4m), iii) average net margin 5.7% (2022: 5.1%), iv) EPS +103% to 222.8p, v) total dividend for the year of 46p (2022: 42p), vi) net assets of £252.4m (2022: £212.0m), NAV per share of 1,547p (2022: 1,411p), vii) CET1 ratio of 13.0% (2022: 11.6%), and total capital ratio of 15.2% (2022: 14.0%).

Arbuthnot Banking Group (ARBB): 2023 - delivering strategy with strong profit growth

United Kingdom

Arbuthnot Banking Group PLC is a United Kingdom-based holding company primarily involved in banking and financial services. It offers private and commercial banking, wealth management, and various asset finance solutions, including specialist asset finance for high-value cars and vehicle finance. The company is headquartered in London, United Kingdom, and was founded in 1833.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arbuthnot Banking Group (ARBB LN)

Chesnara PLC - Hardman & Co Monthly: October 2025

Feature article: Building tomorrow’s AI: How the UK will become the global architect of Trustworthy Intelligence In this month’s feature article,...

Hardman & Co

ICG Enterprise Trust plc - Hardman & Co Monthly: June 2025

Feature article: Addressing the “risk off” investment challenge As we approach mid-2025, life remains challenging for many UK companies and their...

Hardman & Co

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

Hardman & Co Arbuthnot Banking Group (ARBB): 1H’24 - optimising the franchise value

ABG’s 1H'24 results showed the group’s continued evolution to optimise its franchise value. 2023 saw the peak benefits from ABG’s relationship...

Hardman & Co

Arbuthnot Banking Group (ARBB): 2023 - delivering strategy with strong profit growth

The saying goes, the proof of the pudding is in the eating. ABG’s 2023 results proved that the strategic positioning of the group, as a...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)